UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2024 P 2284-3
Program Prior Authorization/Medical Necessity
Medication Vivjoa® (oteseconazole)
P&T Approval Date 8/2022, 8/2023, 8/2024
Effective Date 11/1/2024
1. Background:
Vivjoa (oteseconazole) is an azole antifungal indicated to reduce the incidence of recurrent
vulvovaginal candidiasis (RVVC) in females with a history of RVVC who are not of
reproductive potential.
2. Coverage Criteriaa:
A. Authorization
1. Vivjoa will be approved based on all of the following criteria:
a. Diagnosis of recurrent vulvovaginal candidiasis
-AND-
b. Patient is not of reproductive potential (i.e., persons who are biological females who
are postmenopausal or have another reason for permanent infertility [(e.g., tubal
ligation, hysterectomy, salpingo-oophorectomy)]
-AND-
c. Both of the following:
1) Other causes (including but not limited to bacterial vaginosis or trichomoniasis)
have been ruled out
-AND-
2) Failure of a maintenance course of oral fluconazole defined as 100-mg, 150-mg,
or 200-mg taken weekly for 6 monthsb.
-AND-
d. Prescribed by or in consultation with one of the following:
1) Infectious disease physician
2) Obstetrician/Gynecologist
Authorization will be issued for 4 months.
© 2024 UnitedHealthcare Services, Inc.
1
a State mandates may apply. Any federal regulatory requirements and the member specific
benefit plan coverage may also impact coverage criteria. Other policies and utilization
management programs may apply.
b For Connecticut, Kentucky and Mississippi business, only a 30-day trial will be required.
3. Additional Clinical Rules:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-
authorization based solely on previous claim/medication history, diagnosis codes (ICD-10)
and/or claim logic. Use of automated approval and re-approval processes varies by program
and/or therapeutic class.
• Step Therapy may be in place
4. References:
1. Vivjoa [package insert]. Durham, NC: Mycovia Pharmaceuticals, Inc; April 2022.
2. Sexually Transmitted Infections Treatment Guidelines, 2021. Vulvovaginal Candidiasis
(VVC). Centers for Disease Control and Prevention. https://www.cdc.gov/std/treatment-
guidelines/candidiasis.htm. Accessed July 2024..
Program Prior Authorization/Medical Necessity - Vivjoa
Change Control
8/2022 New program.
8/2023 Annual review. No changes.
8/2024 Annual review. Updated regulatory statement.
© 2024 UnitedHealthcare Services, Inc.
2